Cargando…
Ribaxamase, an Orally Administered β-Lactamase, Diminishes Changes to Acquired Antimicrobial Resistance of the Gut Resistome in Patients Treated with Ceftriaxone
INTRODUCTION: Intravenous (IV) β-lactam antibiotics, excreted through bile into the gastrointestinal (GI) tract, may disrupt the gut microbiome by eliminating the colonization resistance from beneficial bacteria. This increases the risk for Clostridium difficile infection (CDI) and can promote antim...
Autores principales: | Kokai-Kun, John F, Le, Chenxiong, Trout, Kenneth, Cope, Julia L, Ajami, Nadim J, Degar, Andrew J, Connelly, Sheila |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383106/ https://www.ncbi.nlm.nih.gov/pubmed/32801790 http://dx.doi.org/10.2147/IDR.S260258 |
Ejemplares similares
-
1337. SYN-004 (Ribaxamase) Protects the Gut Microbiome of Patients Treated With Ceftriaxone From Disruption and Reduces the Emergence of Antimicrobial Resistance
por: Kokai-Kun, John, et al.
Publicado: (2018) -
The Oral β-Lactamase SYN-004 (Ribaxamase) Degrades Ceftriaxone Excreted into the Intestine in Phase 2a Clinical Studies
por: Kokai-Kun, John F., et al.
Publicado: (2017) -
SYN-004 (ribaxamase) prevents New Onset Clostridium difficile Infection by Protecting the Integrity Gut Microbiome in a Phase 2b Study
por: Kokai-Kun, John, et al.
Publicado: (2017) -
The human gut resistome
por: van Schaik, Willem
Publicado: (2015) -
SYN-007, an Orally Administered Beta-Lactamase Enzyme, Protects the Gut Microbiome from Oral Amoxicillin/Clavulanate without Adversely Affecting Antibiotic Systemic Absorption in Dogs
por: Connelly, Sheila, et al.
Publicado: (2020)